Pharma BD Deal Intelligence
Daiichi Sankyo Company, Limited / Ambit Biosciences
2006 · Acquisition/Merger · $410M · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
62
Largely worked — most objectives met.
Daiichi Sankyo acquired Ambit Biosciences for ~$410M for cancer compound quizartinib.
Key facts
- Announced Apr 27, 2006
- Closed Nov 10, 2014
- Deal value $410M
- Deal type Acquisition/Merger
- Therapeutic area Oncology
- Key assets quizartinib
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals